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Abstract
Background: The Labcor Dokimos Plus (LDP) is a stented externally mounted pericardial aortic bioprosthesis, which
was recently introduced in Europe. Aims of the study are evaluation of operative and postoperative results as well
as hemodynamic performance.
Methods: One hundred consecutive patients with a mean age of 65.9 ± 10.7 years (range 35–87) and a mean
EuroSCORE II of 3.1 ± 3.9 (range 0.67–24.5) underwent aortic valve replacement with the LDP. Mean valve-size was
25.2 ± 1.7 mm. Concomitant procedures were performed in 34% of the cases. Postoperative clinical data were
analyzed and hemodynamic performance of the prostheses was evaluated by transthoracic echocardiography.
Clinical follow-up was 100%, echocardiographic follow-up was 93% complete.
Results: Intraoperatively no peculiarities occurred. Mean cross clamp times for isolated and complex procedures
were 74.5 ± 20.0 min and 103.7 ± 37.1 min, respectively. Patients were extubated after a mean of 9.4 ± 15.8 h. There
were no perioperative strokes. Bleeding events occurred in 4 patients. 30-day-mortality was 2%. One case of early
endocarditis occurred. Echocardiography showed maximum and mean pressure gradients of 18.1 ± 6.4 and 9.6 ± 3.
7 mmHg, respectively. Correspondingly to valve sizes 21, 23, 25 and 27 mm, mean pressure gradients were 17.3, 9.5,
8.5 and 10.2 mmHg, effective orifice areas were 1.92, 1.79, 2.0, 2.16 cm2 and indexed effective orifice areas were 1.
08, 0.95, 0.99 and 1.01 cm2/m2, respectively. No relevant regurgitations occurred.
Conclusions: The LDP showed operatively no peculiarities and a satisfactory clinical outcome with low
perioperative morbidity and mortality. The hemodynamic performance of the implanted valve sizes was satisfactory.
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Background
Recently, a new bovine pericardial stented bioprosthesis
for the aortic position, the Labcor Dokimos plus (LDP),
became available in Europe. The design features are a low
profile stent with externally mounted leaflets [1]. Yet, no
contemporary data about clinical outcome and
hemodynamic performance are available. We report about
our perioperative experience with this substitute, the early
clinical outcome and hemodynamic performance.
Methods
Patients
From October 2013 to February 2015 100 consecutive
patients underwent aortic valve replacement with LDP
prostheses, while a total of 358 patients received an
aortic valve replacement at our institution. The decision
to implant the bioprosthesis was made according to the
actual guidelines [2, 3]. Baseline preoperative character-
istics are displayed in Table 1.
Prosthesis
The LDP prosthesis, manufactured in Labcor Laborator-
ies, Belo Horizonte, Brazil is a CE-marked stented bo-
vine pericardial bioprosthesis and available in sizes from
19 to 27 mm (Fig. 1). Special features of this prosthesis
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are a low profile, an acetal copolymer stent covered with
polyester, externally mounted pre-molded leaflets fixed
with glutaraldehyde at zero pressure as well as a so
called Reducer® anti-calcification treatment.
Surgical technique
A right upper hemisternotomy in the 4th intercostal
space was performed for isolated aortic valve replace-
ment and full sternotomy for combined procedures.
Standard cannulation of the ascending aorta and the
right atrium was performed in all cases except in two
patients with additional tricuspid valve repair. In these
cases bicaval cannulation was performed. Usually
normothermic perfusion was used. However, in complex
cases with impaired ventricular function mild
hypothermia (32–34 °C) was applied. After clamping of
the aorta, intermittent antegrade blood cardioplegia ac-
cording to Calafiore was performed. The ascending aorta
was transversely opened 1–2 cm above the commissures
for half of its circumference. After resection of the dis-
eased valve and thorough annular decalcification, sizing
with ball-sizers and LDP-sizers was performed. The ap-
propriate prosthesis was implanted with 12–20 horizon-
tal felt-armed mattress sutures. The prosthesis was
positioned either supra-annularly or intra-annularly de-
pending on the distance between the aortic annulus and
the coronary ostia, the position of the coronary ostia,
calcifications in the coronary sinus and the size of the
annulus and the sinus coronarius. The intra-annular
position was chosen in patients with tubular sinuses,
possible coronary obstruction by the bioprosthesis and
in patients with aortic annuli above 29 mm. In smaller
annuli (≤21 mm), stentless valves were implanted
(according to institutional guidelines), what represents a
selection bias for this study. Mitral valve procedures
(with or without left atrial ablation), distal coronary
anastomoses and aortic annular enlargement were per-
formed before implantation of the LDP. Tricuspid pro-
cedures were performed on the beating heart after the
aortic valve replacement. Aortic annular enlargement
was done using the Manouguian technique using a patch
of bovine pericardium to reconstruct the extended aor-
totomy into the non-coronary cusp and the subaortic
curtain. The function of the prosthesis was controlled by
trans-esophageal echocardiography.
Clinical follow-up
After approval by the local Ethics Committee pre-, intra-
and early postoperative (until discharge) data were pro-
spectively collected. Hemodynamic performance was
evaluated using transthoracic echocardiography at dis-
charge. It was performed with a GE Vivid 7 Dimension
(General Electric, Fairfield, Connecticut, USA) to check
morphology and function of the implanted prostheses.
Table 1 Baseline characteristics and risk stratification
Characteristic Number
Number of patients (n) 100
• Age in years ± standard deviation 65.9 ± 10.7
Gender
• Male (n) 77
• Female (n) 23




• Stenosis (n) 55
• Regurgitation (n) 25
• Mixed lesion (n) 20
• Active endocarditis (n) 9
Predominant cardiac rhythm
• Sinus rhythm (n) 73
• Atrial fibrillation (n) 27
Concomitant disease
• Coronary artery disease (n) 38
• Arterial hypertension (n) 67
• Pulmonary hypertension (n) 7
• Renal dysfunction (n) 32
• Diabetes mellitus (n) 22
• Obesity (n) 30
NYHA class (Mean ± standard deviation) 2.6 ± 0.7
EuroSCORE II 3.1 ± 3.9
Range: 0.7-24.5
• Isolated aortic valve replacement 2.0 ± 1.7
Range 0.7-8.2
• Complex procedures 5.9 ± 3.8
Range 0.7-24.5
Fig. 1 Lateral view and front view of the Labcor Dokimos Plus
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Two-dimensional and Doppler transthoracic echocardi-
ography was performed. Mean values for each measure-
ment were derived from three beats in sinus rhythm,
and five beats in those in non-sinus rhythm. Transaortic
flow velocities were assessed by continuous–wave Dop-
pler, while flow velocities in the left ventricular outflow
tract were assessed by pulsed–wave Doppler. Pressure
gradients were calculated using the Bernoulli equation.
The effective aortic valve orifice area (EOA) was calcu-
lated with the continuity equation and indexed by the
body surface area of the patient (EOAI).
Statistics
All data were prospectively collected and analyzed with
SPSS Statistics version 22.0.0 (SPSS Inc., Chicago,
Illinois). Descriptive statistics are reported as the mean
± standard deviation for continuous variables and as ab-
solute frequencies and percentages for categorical
variables.
Results
Operative details are presented in Table 2. Smaller valve
sizes (≤21 mm) were implanted rarely, due to institu-
tional guidelines to implant stentless valves in these
cases. Intra-annularly implantation of the LDP was per-
formed due to a wide aortic annulus (>29 mm, n = 23),
possible coronary obstruction (n = 18) and calcification
or anatomical anomalies of the Valsalva sinuses (n = 16).
Supra-annularly implantation was performed in the rest
of the patients. No intraoperative complications oc-
curred and intraoperative mortality was 0%. Patients
were extubated after a mean of 9.4 ± 15.8 h. Three pa-
tients developed a low cardiac output syndrome postop-
eratively and therefore received extracorporeal life
support (ECLS) within the first 24 h after the operation.
These patients had undergone complex combined proce-
dures and suffered preoperatively from an impaired left
ventricular function with a left ventricular ejection frac-
tion ≤ 35%. ECLS could be weaned in two patients at the
4th and 5th day postoperatively, respectively. However,
both patients died due to intractable ventricular fibrilla-
tion and septic multi-organ failure at the 9th and 44th
postoperative day, respectively. The third patient died at
the 6th postoperative day due to multi-organ failure. No
other fatalities occurred. Hence, in patients with com-
plex procedures the 30-day mortality was 5.9% and the
hospital mortality 8.8%. For patients undergoing isolated
valve replacement the 30-day mortality was 0%.
Postoperative complications included re-exploration
for bleeding, which had to be performed in four patients.
Furthermore, eight patients developed acute renal insuf-
ficiency and required temporary dialysis. Insertion of a
permanent pacemaker became necessary in six patients.
There were no strokes or deep sternal wound infections.
One case of early postoperative endocarditis occurred,
which led to a successful secondary valve replacement at
the 30th postoperative day. Patients were discharged
after a mean of 10.5 ± 6.9 days.
Echocardiography was analyzed for 93% of the cases.
Excluded were data of 7 patients, due to insufficient
conditions early postoperatively (n = 4), death (n = 2; pa-
tients with ECLS, who died on the 6th and 9th day post-
operatively) and endocarditis (n = 1). Maximum and
mean prosthetic pressure gradients at discharge were
18.1 ± 6.4 and 9.6 ± 3.7 mmHg, respectively. Mean EOA
and mean EOAI were 2.01 ± 0.52 cm2 and 0.99 ±
0.25 cm2/m2, respectively. Two cases of severe patient-
prosthesis mismatch (EOAI < 0.65 cm2/m2) were ob-
served (mean body mass index in these patients was
33.3). Twenty-one cases of moderate prosthesis-
mismatch (EOAI > 0.65 cm2/m2 and < 0.85 cm2/m2)
were observed. No relevant central or para-valvular re-
gurgitation was evident. No structural or nonstructural
valve dysfunctions and no valve thrombosis could be
Table 2 Operative characteristics
Procedure Number
Isolated aortic valve replacement (n) 66
Combined procedures (n) 34
• Coronary artery bypass grafting (n) 21
• Mitral Valve Replacement (n) 5
• Mitral Valve Repair (n) 3
• Left atrial ablation (n) 3
• Ascending Aorta Replacement (n) 2
• Tricuspid Valve Reconstruction (n) 2
• Aortic Annular Enlargement (n) 2
Implanted valve sizes
• 21 mm (n) 3
• 23 mm (n) 20
• 25 mm (n) 41
• 27 mm (n) 36
Technique of implantation
• Supra-annularly (n) 40
• Intra-annularly (n) 60
Duration of procedure (min) 212.4 ± 57.7
• Isolated procedures (min) 189.2 ± 36.3
• Combined procedures (min) 257.2 ± 65.4
Cardiopulmonary bypass time (min) 113.6 ± 40.6
• Isolated procedures (min) 96.6 ± 25.3
• Combined procedures (min) 140.2 ± 45.7
Aortic cross clamp time (min) 84.8 ± 30.0
• Isolated procedures (min) 74.5 ± 20.0
• Combined procedures (min) 103.7 ± 37.1
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observed. Table 3 provides the detailed hemodynamic
data according to the different valve sizes.
Discussion
Conventional aortic valve replacement is still a gold
standard for patients with relevant aortic valve disease
without excessive risk profile. Biological substitutes are
recommended for patients older than 65 years or those
with contraindications to systemic anticoagulation [2, 3].
Stented biological substitutes are easy to implant and
show acceptable hemodynamic performances. However,
there is still the necessity to improve these valves con-
cerning hemodynamic properties and clinical perform-
ance as well as durability. The LDP was launched in
Europe in 2013. It´s innovative design combined with a
novel anti-calcification treatment makes it a promising
substitute in the category of stented bioprostheses. To
our knowledge, this is the first study that reports early
postoperative outcome and hemodynamic data in a
European population.
Procedural data, including cross clamp times, were
comparable to other stented bio-prosthetic heart valves
and verify the simplicity and safety of the LDP-
implantation [4–6]. However, one has to consider the
low mean age and predicted risk of the study cohort,
which was triggered by the increasing use of transfe-
moral aortic valve replacement in our institution in
older high risk patients. Noticeably, intra-annularly im-
plantation occurred very frequently. This is triggered by
the institutional guideline to implant stentless valves in
smaller annuli, which leaves the stented valves for larger
annuli, where in turn intra-annularly implantation can
be advantageous. This proceeding also led to a predom-
inant male study population, by eliminating female pa-
tients with small annuli. Consequently, 64% of valve size
27 mm was implanted intra-annularly.
The early clinical results after implantation of the LDP
were within normal limits for bioprostheses. The post-
operative course of most patients was uneventful. How-
ever, the need of permanent pacemakers in six patients
was slightly higher than reported for the SJM Trifecta
[7]. Moreover, there were eight patients requiring tem-
porary dialysis postoperatively. However, those patients
were multi-morbid and all but one had undergone com-
plex procedures. The 30-day mortality of 2.0% was lower
than the EuroSCORE II predicted mortality (3.1 ± 3.9%),
which is actually one of the best predictors for hospital
mortality after aortic valve replacement [8].
At first glance, hemodynamic data of the LDP in this
study were conclusive. Mean results, regarding pressure
gradients, EOA and EOAI were comparable or even bet-
ter than other bioprostheses, like the St. Jude Medical
Trifecta, the Sorin Mitroflow, the Medtronic Mosaic or
the Sorin Freedom Solo [6, 9–11]. While analyzing these
data it´s to consider, that the body surface area of our
study population was relatively high (but normal and
typical for German inhabitants), which lowered the
EOAI results. Additionally, only two cases of severe
patient-prosthesis-mismatch were evident. These cases
occurred in obese patients with valve size 25 mm, where
obesity biased (lowered) the EOAI by causing a higher
body surface area. Notably, also 8 of the 21 patients with
moderate-patient-prosthesis mismatch were obese (body
mass index above 30). But at second glance,
hemodynamic outcome with regard to the labelled valve
sizes showed conflicting results in comparison to various
other available bioprostheses. For this evaluation, data of
the 21 mm LDP was not considered, due to the low
number of cases. Data for valve-sizes 23 mm and 25 mm
were comparable to data published for the SJM Trifecta
regarding pressure gradients, EOA and EOAI [7, 12]. In
contrast, data for size 27 mm showed inferior results
than the SJM Trifecta. The comparison to the Sorin
Mitroflow, a stented pericardial bioprostheses, showed
comparable pressure gradients for valve-sizes 23 mm
and 25 mm, whereas LDP size 27 mm showed higher
gradients [9]. The EOAI of the Sorin Mitroflow was
lower for all valve sizes, but the gap to the LDP was
closest for the 27 mm prosthesis. The Medtronic
Mosaic, a stented porcine bioprostheses, showed higher
mean pressure gradients for valve sizes 23 mm and
25 mm and comparable values for size 27 mm [10].
Upon consideration of the EOA of the Medtronic
Mosaic, values were comparable for valve sizes 23 mm
and 25 mm, and higher for size 27 mm [10]. The first
generation porcine stentless valves (Medtronic Freestyle,
Table 3 Echocardiographic results according to labeled valve sizes
Valve size (mm) 21 23 25 27
Number 3 18 39 33
Mean Pressure
Gradient in mmHg
17.3 ± 6.7 9.6 ± 3.0 8.5 ± 3.1 10.2 ± 3.6
Maximum Pressure gradient in mmHg 29.7 ± 12.1 19.3 ± 4.9 16.5 ± 5.8 19.1 ± 5.8
Effective Orifice Area
in cm2
1.92 ± 0.44 1.79 ± 0.36 2.0 ± 0.6 2.16 ± 0.47
Indexed Effective Orifice Area in cm2/m2 1.08 ± 0.33 0.95 ± 0.18 0.99 ± 0.29 1.01 ± 0.24
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SJM Toronto) showed a clear disadvantage in terms of
pressure gradients and EOA [13, 14]. On the contrary,
the latest generation of pericardial stentless valves
showed lower transvalvular gradients compared to our
data [11]. Even so, the EOAI of these valves was only
slightly above results of the LDP, but once again with
the widest gap for valve size 27 mm [11]. According to
the comparison with these studies, valve sizes 23 mm
and 25 mm showed excellent hemodynamic properties,
while a slightly impaired function of valve size 27 mm
was evident. Possibly, the high percentage of intra-
annularly implanted valves in this size has an impact,
due to the change of the hemodynamic flow pattern
caused by the stent in the aortic annulus. However, our
results showed no difference between the intra-annular
and the supra-annular position for valve size 27, possibly
due to the low number of cases. Hence, further studies
with larger cohorts and a higher number of implants per
size are required. Additionally, longer follow-up is neces-
sary to confirm these findings in mid-term and long-
term follow-up.
Conclusion
The Labcor Dokimos Plus was easy to implant, offered op-
eratively no peculiarities and patients showed a satisfactory
clinical outcome. Hemodynamic results were pleasing.
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